Lawsuits involving the anticoagulant Xarelto continue to mount in the U.S. and Canada. The popularity of the relatively new drug is due, at least in part, to its convenience for the consumer as it does not have the dietary restrictions or stringent monthly blood-testing required by that the established blood thinner, Coumadin (warfarin). Xarelto (rivaroxaban), however, was put on the market with no available antidote, according to Lawyers and Settlements.com.
In September 2012, a Calgary woman came dangerously close to having a heart attack after she suffered internal bleeding while using Xarelto, according to the Calgary Sun. “They advised her that Xarelto was the cause of her hemorrhaging and that, unlike other anticoagulants such as warfarin, there was no way to reverse the effects of Xarelto.” The health care professionals that cared for the woman said they had considerable difficulty stopping her bleeding.
The Canadian counterpart to the U.S. Food and Drug Administration, Health Canada, recorded 1,100 adverse effects tied to Xarelto, according to the Xarelto side-effects class action suit. The lawsuit states, “A dozen of those adverse effects registered with Health Canada indicated that death had resulted from Xarelto,” reports Lawyers and Settlements.com.
It was reported that a lawsuit was expected on behalf of an 83-year-old woman from Ontario who bled to death in the shower in November 2013.
At this time, plaintiffs say had they been aware Xarelto was made available to the public before an effective antidote or reversing agent was to be had, they would have stayed with warfarin. Plaintiffs also allege that Bayer was negligent in appropriately promoting Xarelto “as requiring less monitoring, when a reversing agent was not yet available to help with Xarelto bleeding complications,” Lawyers and Settlements.com reports.